Entinostat shows which users are most likely to have delayed breast cancer progression - ONA
Links shared publicly online about this topic.
- 0total visits
Entinostat shows which users are most likely to have delayed breast cancer progression - ONA
Clinical outcome can be predicted shortly after administration of the HDAC inhibitor entinostat among women with metastatic breast cancer, according to the company that developed the agent.
View full resource at oncologynurseadvisor.com
Tags: Cancer, Breast Cancer, Metastatic Breast Cancer, Women's Health
Most Recently Shared on November 24, 2011 at 10:45 pm By:
#Entinostat shows which users are most likely to have delayed breast cancer progression http://t.co/6uXf173D #breastcancer
Advertisement
